Smart packaging has become an active field of research in various industries as the need to track goods through the supply chain escalates. Significant work is underway among various stakeholders to identify and commercialize smart packaging technologies, especially in the healthcare, electronics and energy industries.
New analysis from Frost & Sullivan, Technical Insights, Impact Assessment of Smart Packaging in Healthcare, Electronics, and Energy, finds that smart packaging for healthcare and electronics products is the most developed. Adoption of smart packaging for pharmaceuticals, in particular, will increase rapidly owing to a growth in ageing populations in the western world and concerns surrounding drug counterfeiting and overdoses. Smart packaging for energy is still in an early stage.
Senior Industry Analyst Aarthi Janakiraman commented, "With consumers in healthcare and electronics, especially, demanding sophisticated packaging that can detect exposure to environmental factors, maintain humidity, and act as a drying agent, there is every reason to see more products being sold commercially."
Hurdles to commercializing the technology, according to the report, include the disparity in regulations across countries, particularly, stringent laws in Europe and North America, the perceived high cost of active and intelligent packaging, aas well as potential privacy concerns with smartphones, and low public acceptance currently. Customers need to be educated about the technology.
"Environmentally-friendly, tamper-proof, and lightweight packaging will be the next step for the industry," claimed Janakiraman. "Advances geared toward miniaturization, non-invasive sensing of packaging equipped with smart displays and radio-frequency identification tags will lend momentum to the use of next generation packaging in healthcare, energy and electronics applications."
Technical Insights is an international technology analysis business that produces a variety of technical news alerts, newsletters, and research services.
Wearable medical devices are expected to have a major impact on the healthcare sector, but data security will remain a concern.
However, despite well documented security risks, worldwide revenues of wearable medical devices are expected to explode from $2.8 billion in 2014 to $8.3 billion in 2019, according to analyst firm Mordor Intelligence.
The potential benefits that wearables in the healthcare sector offer are many. They are expected, for example, to enable patients to have constant access to their complete health records. In this way, patients can share information in real-time with physicians, insurance companies, and other parties. Massive volumes of data transferred from wearables could be a goldmine of valuable information for researchers and clinicians.
Wearables will also represent a significant shift in how patients transfer, access, and ultimately control data shared with physicians, representing a great change in patient-doctor relationships. “Traditionally, 80% of the time the doctor has controlled your information and 20% of the time you have. But with wearables, consumers will have much more control of their information and what they choose to do with it,” Mick Coady, principal, U.S. health services for PricewaterhouseCoopers (PwC), said. “The patients as well as the physicians will arrive at the doctor’s office much more informed via wearables.”
However, security risks and concerns will have to be resolved if wearables will realize their potential in the marketplace.
As is the case when any kind of personal data is shared, security risks are involved when the data is transferred over networks and when third parties store the information on their databases.
"The reality is that wearables and mobile health/wellness/fitness applications do involve security risks in data storage and data movement that increases risks of security breaches,” Greg Caressi, senior vice president of healthcare and life sciences for Frost and Sullivan, said.
Among the two major security risks, information transferred from devices to databases pose the least threat. This is because the data transferred will largely consist of incomplete information about the patient when the wearable transfers it. Individual data points about blood pressure, glucose levels, or other specific health-related information usually does not pose a significant threat if intercepted by a hacker individually.
“[Data thieves] are probably not going to want or need only a portion of your medical information that is coming off wearables, such as heart rate, calorie intake, or oxygenation in the blood,” Coady said. “What is the relevance of it being associated with your name and your record in totality that could be used to commit fraud or identity theft?”
Data thieves will thus likely not be as interested in stealing less-valuable information about very specific patient data. But a database that a healthcare service or insurance company manages that has complete medical history information that wearables have uploaded over the course of time is a much more lucrative target. “It is your name and record in totality that is of value,” Coady said.
Often overlooked, data collected on a massive scale for research purposes also represent a major security threat.
“Privacy and security are paramount when it comes to patient data and the data collected in a clinical trial. Any data captured from wearable devices used for clinical trials must be highly secure,” Kara Dennis, vice president, chief of staff, Medidata Solutions, said. “While there is still a lot of hard work ahead to understand the best ways to use wearable devices in clinical trials and to understand how mobile health data relates to traditional clinical measures, we’re excited by the potential of wearable, consumer-grade device. They should provide more comprehensive, nuanced insight into the health status of patients and the progression of disease.”
The good news is that existing laws, mandates, and regulations such as HIPAA should largely cover the encryption of data transfer and storage of wearable medical devices.
“Physicians and insurance companies have had a few years to become compliant and to abide by the laws in place, etc.,” Coady said. “So while wearables are a new technology that consumers are adopting, the parties storing the information have had a few years under their belt to properly store the data in a reasonably secure way that is compliant with existing laws, mandates, and regulations.”
Considering the potential benefits that wearables offer the healthcare industry, device makers, third-party medical service providers, and consumers will likely accept the security threat the devices pose on a massive scale--if vendors, healthcare providers, and other parties involved can demonstrate that they can adequately protect the data.
"I think that like other data risks we encounter in the financial and employment worlds, we will be willing to trade off these risks for the benefits we are likely to accrue. Most wearable and telehealth solutions involve major gains for the individual in insight into their health, enable them to better self-manage their health, and add in the value of convenience that the brick-and-mortar healthcare world does not provide,” Caressi said. “More than most of the security risks we encounter, wearables are something we ultimately control as a choice we make individually, so individuals will be able to decide ourselves if the risk is worth it for themselves. While there will eventually be some scare articles that come out when a significant security breach occurs, and it will have a small impact on the drive to add personal sensors to our daily lives, I don't think it will derail the wearable movement over the long term."
Growing at a rapid pace, BeyonDevices is to a great extent becoming a strong benchmark in patient care and compliance by developing completely innovative medical devices.
Recently BeyonDevices was distinguished with the first prize for Healthcare Excellency at a contest organized by “DNA Cascais” a non-profit organization which aims to, contribute, using every adequate mean, for the promotion, incentive and development of entrepreneurship in general, especially focused on promoting social and young entrepreneurship in Cascais (Portugal). The contest in which BeyonDevices participated is purposed to promote and reward business Excellency and innovation.
After a careful examination, the judges selected 22 companies to pass to the final stages of the contest, among these 22 companies there were 3 companies which were applying to win the first prize in Healthcare, one them being, of course, BeyonDevices.
After having developed and introduced in the market its one of a kind Vaginal Drug Delivery System (VDDS), BeyonDevices is now guaranteeing that its innovative Dry Powder Inhalator (DPI) has the same impact on the market as its VDDS, in that sense BeyonDevices attended to the most prestigious event on Respiratory Drug Delivery: RDD Europe 2013.
Beyondevices saw this event as a very important opportunity for networking and securing important bonds within the inhalation speciality. It is empirical for BeyonDevices to keep up with leading world class events and novelties regarding its area of activity. As planned, BeyonDevices is growing at a quick pace and is making itself being noticed among big players for its ground-breaking Drug Delivery Devices and Smart Packaging Solutions.
BeyonDevices has just completed one year since it was created. This flexible and fast-growing start-up does not cease to surprise!
Since April 2012, BeyonDevices has developed and enriched several smart packaging solutions. From its state-of-the-art VDDS (Vaginal Drug delivery System), a device which came to revolutionize the women’s healthcare industry; to its ground-breaking DPI (Dry Powder Inhaler), one device which gains from simplicity yet primes for quality, and many others such as the Senior-Friendly and its One-by-One Single Dispensing unit, BeyonDevices’ products will continue to surprise anyone in the Healthcare industry, as it has been doing.
Moreover this “one year old” company has made itself represent in already 3 major Packaging-Specialized European exhibitions, and always coming back with plenty of success as it never goes unnoticed by visitors coming from all parts of the globe.
Creativity and hard work are definitely key for a small company to prosper in this time of economic downturn.
This collaboration will lead to a wide range of E-communicative Devices and Packagings.
The first products as a result of this cooperation between Qolpac and BeyonDevices, with OtCM inside, will be an innovative Dry Powder Inhaler for efficient pulmonary drug delivery and the OtCM Cap for the standard Rexam Pillboxes widely used in the USA.
BeyonDevices focuses on the development of innovative medical devices and medical technology while improving patient compliance through smart packaging, with the purpose of exploring niche markets in the Pharmaceutical Primary Packaging as well as Medical Technology & Device Industries.
BeyonDevices brings to the market leading innovative solutions for drug delivery, having recently introduced in the women’s health market segment its patented and radically innovative vaginal applicator and has developed in the area of pulmonary drug delivery a novel DPI system, which presents a significant element of in-house innovation in the powder dispersion technology, as well as focusing from the onset on improved consumer convenience and safety and presenting to manufacturers an off-the-shelf economic alternative to current market leading product.
BeyonDevices integrates the top Portuguese Health Companies Cluster.
BeyonDevices has been accepted as a HCP (Health Cluster Portugal) member. After being founded in April 2012, BeyonDevices - a young Medical Devices company which is growing at a fast pace - is already planning to launch more new products in 2013 following the success of its new state-of-the-art vaginal applicator.
The Health Cluster Portugal (HCP) (www.healthportugal.com) is a national cluster that assumes as its mission to turn Portugal into a more competitive player in the research, design, development, manufacturing and commercialization of health-related products and services, in selected market and technological niches, targeting the most demanding and relevant international markets, based on the recognition of its excellence, technological level and competences in the field of innovation. – Health Cluster Portugal
Following the acceptance to enter this prestigious group of leading Health Companies and Institutions, BeyonDevices is focused on its quest to become a leader on R&D of innovative health devices, both internally and through partnerships. BeyonDevices plans to follow with the presentation of its DPI (Dry Powder Inhaler) platform in 2013. This device will prime for its ease of assembly, use, and its low price, yet with high standards of quality and efficiency.
We are proud to see how BeyonDevices is turning out to be such a great success and hope to continue with this sense of achievement throughout 2013.
BeyonDevices as a HCPC guest to discuss ways to improve patient adherence through packaging.
António Ornelas Soares, BeyonDevice’s Business & Market Development Director brought with him a full range of new ideas and concepts after having participated as an invited industry expert at the HCPC’s Experts’ Round Table Discussion on Patients’ Adherence and Drug Packaging at the Hotel Villa de la Reina, at the same time that the CPhI Worlwide event was taking place at the Feria de Madrid.
Lack of patient’s adherence is currently an issue of extreme importance for the whole Health Value Chain, namely to the Pharma industry as it also can be for society and to national governments; when patients do not follow the appropriate therapeutic measures not only they worsen their health condition but also national healthcare institutions resources resulting in increasing extra costs.
During the meeting the participants brought up several ideas to address this problem and together reached the conclusion that even though the present health industry players gradually seems to differentiate the link involving adherence and possible monetary payback, corporations frequently do not know how to increase adherence. As a result, it is mandatory to emphasize that packaging symbolizes one significant panorama to improve adherence. Until this day packaging is mostly put apart, unconsidered neither as a means for communication with patients nor as an option to improve adherence. While some firms are already working on adherence-enhancing and other packaging characteristics, it is of extreme importance and urgency to introduce measures that increase awareness of this issue for the whole Pharmaceutical industry. Over and over again one has to underline that packaging is a way to transmit information and that it is a means to communicate with patients so as to assist adherence.
BeyonDevices is a new company born of the experience acquired through Neutrodevices, a spin-off of Neutroplast, and other partners in the biotechnology and medical devices sector. BeyonDevices now offers new tools that enable it to maintain a stronger presence in the market by offering additional know-how to its customers in critical areas, such as in women’s health and inhalation devices.
BeyonDevices expects to bring an extended solution to the market, all the way from design through to industrialization. The company will offer this not only for the devices developed through NeutroDevices (where the firm launched its first device, a vaginal applicator), but also for products where the IP belongs to customers in the designated areas.
To forward that goal, BeyonDevices offers a comprehensive range of services, including creating smart packaging solutions, mould design, material selection, packaging design and development, product design and development, process development, tool management and testing and validation. Additionally, the company offers a diversity of capabilities with regard to medical technology or device design.
Right after having been founded by Neutroplast, as a new spin-off, BeyonDevices quickly decided to hire a recent graduate directly from the most prestigious engineering university in Portugal, and one of the best in Europe: Instituto Superior Técnico. Consequently, Mafalda Manata Santos is now the new Assistant for Business & Market Development at BeyonDevices.
Mafalda studied biological engineering with the purpose of “improving people’s quality of life through technology” (Mafalda), this course is one of the most distinguished according to European standards and in that sense it has been reviewed and approved with the Eur-Ace label.
Following a summer internship at BeyonDevices, Mafalda was hired with the purpose of helping this brand new spin-off to build a base from which to start to market its brand as one of the most well-recognized and innovative companies in the field of device and project development. This requires the integration of different technologies and a profound knowledge of manufacturing expertise.
Currently Mafalda, along sides António Soares, a very experienced professional in the area of business development and innovation, are organizing all that is needed to employ the ISO 15378, the NP4457, at BeyonDevices in order to prepare the launch of BeyonDevices’ first product to enter the consumer market. This will be its new state of the art vaginal applicator for which BeyonDevices started to get pre-orders even before the applicator was ready to market.